when were glp 1 agonists approved Continued growth for GLP-1 receptor and SGLT-2 inhibitors in 2017 GLP-1 Receptor Agonists – From

It showed that the relative risks for aspiration, aspiration pneumonia, pneumonia, or respiratory failure were not elevated in patients prescribed GLP-1 RA compared to those receiving dipeptidylpeptidase-4 (DPP-4) inhibitors [21]

In the treatment-policy estimand analysis, at week 26 oral semaglutide (1.2% mean A1C reduction from baseline) met criteria for noninferiority when compared with liraglutide (1.1% mean A1C reduction from baseline) and met criteria for superiority when compared with placebo (0.2% mean A1C reduction from baseline

Dosing is individualized, but a typical protocol titrates from a starting dose up to a target dose over 2 to 4 weeks, injected 5 days on and 2 days off, in defined cycles with scheduled breaks between them

Consistent use leads to gradual skin lightening until the desired complexion is achieved